Chemotherapy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Chemotherapy refers to the use of cytotoxic (cell-killing) chemical agents — individually or in combination regimens — to treat cancer by destroying rapidly dividing malignant cells throughout the body. Unlike surgery or radiotherapy, which are localised treatments, chemotherapy is a systemic therapy capable of reaching cancer cells at any anatomical site, making it essential for treating cancers that have spread beyond the primary site or are at risk of microscopic distant spread. Chemotherapy drugs primarily act by interfering with DNA replication, cell division, or other cellular processes that rapidly dividing cells depend upon more than normal cells.

Chemotherapy is used in multiple contexts across oncological care: as primary (induction) treatment for haematological malignancies such as leukaemia and lymphoma, where it is often curative; as neoadjuvant (pre-operative) treatment to shrink solid tumours before surgery, increasing the likelihood of complete resection; as adjuvant (post-operative) treatment to eliminate residual microscopic disease after surgery, reducing the risk of recurrence; as concurrent sensitisation during radiotherapy for certain cancers; and as palliative treatment in advanced cancers to control disease, relieve symptoms, and prolong survival without curative intent.

Chemotherapy is administered in cycles — typically every two to four weeks — allowing normal tissues time to recover between doses while maintaining cumulative toxicity on cancer cells. Regimens are defined by specific combinations, doses, and schedules that have been established through clinical trials as providing the optimal balance of efficacy and tolerability. Modern oncology integrates chemotherapy with targeted therapies, immunotherapy (checkpoint inhibitors), hormone therapy, and locoregional treatments in multidisciplinary tumour board-guided treatment plans.

Breast cancer is the most commonly chemotherapy-treated solid tumour globally. Standard regimens include doxorubicin/cyclophosphamide (AC) followed by a taxane (paclitaxel or docetaxel) — the AC-T regimen — as adjuvant or neoadjuvant chemotherapy. HER2-positive breast cancer is treated with chemotherapy combined with HER2-targeted agents (trastuzumab, pertuzumab). Triple-negative breast cancer (TNBC) benefits from platinum-based chemotherapy (carboplatin) and immunotherapy (pembrolizumab) in neoadjuvant regimens.

Colorectal cancer is treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) or FOLFIRI (fluorouracil, leucovorin, irinotecan) as adjuvant therapy post-resection and for metastatic disease, often combined with bevacizumab or cetuximab/panitumumab. Lung cancer chemotherapy varies by histology: NSCLC treated with platinum doublets (cisplatin or carboplatin with paclitaxel, gemcitabine, or pemetrexed) often combined with immune checkpoint inhibitors (pembrolizumab); SCLC with cisplatin or carboplatin plus etoposide. Haematological malignancies — diffuse large B-cell lymphoma (R-CHOP), acute lymphoblastic leukaemia (hyper-CVAD), acute myeloid leukaemia (7+3 induction) — rely heavily on chemotherapy-based regimens, often with curative intent.

Eligibility for chemotherapy is determined by the cancer type and stage, the therapeutic intent (curative or palliative), available alternatives, and the patient's functional status and organ reserve. The ECOG performance status (0–4 scale) is the standard measure of functional fitness; most chemotherapy protocols require ECOG 0–2. Key organ function assessments include cardiac function (ejection fraction by echocardiogram before anthracyclines), renal function (creatinine clearance for cisplatin and carboplatin dosing), liver function (for hepatic metabolism of many agents), and bone marrow reserve (full blood count). Age alone is not an absolute contraindication; physiological fitness and comorbidity burden determine tolerance.

Contraindications to specific agents include impaired renal function below specified thresholds for platinum compounds, severe heart failure or pre-existing cardiomyopathy for anthracyclines (cardiotoxic), peripheral neuropathy for taxanes and platinum agents (neurotoxic), and active infection at the time of planned administration. Pregnancy requires careful individual assessment — some agents are teratogenic in all trimesters; others may be used with caution in the second and third trimesters. Patients with autoimmune conditions require careful discussion before immune checkpoint inhibitor combinations, as pre-existing autoimmunity increases the risk of immune-related adverse events.

Chemotherapy drug classes differ by mechanism of action: Alkylating agents (cyclophosphamide, ifosfamide, cisplatin, carboplatin, oxaliplatin) covalently cross-link DNA strands, preventing replication. Antimetabolites (methotrexate, 5-fluorouracil, capecitabine, pemetrexed, gemcitabine) mimic normal metabolites to disrupt DNA and RNA synthesis. Anthracyclines (doxorubicin, epirubicin, daunorubicin) intercalate into DNA and inhibit topoisomerase II, causing strand breaks. Taxanes (paclitaxel, docetaxel, nab-paclitaxel) stabilise microtubules, preventing cell division. Vinca alkaloids (vincristine, vinblastine, vinorelbine) inhibit microtubule polymerisation. Topoisomerase inhibitors (irinotecan, etoposide) prevent DNA uncoiling during replication.

Administration routes include intravenous infusion (most agents), oral tablets (capecitabine, cyclophosphamide, temozolomide), intrathecal injection (methotrexate, cytarabine for CNS disease), and intraperitoneal delivery (HIPEC — hyperthermic intraperitoneal chemotherapy — for peritoneal surface malignancies). Cycle intervals vary from weekly (paclitaxel for breast cancer) to every three weeks (AC-T, FOLFOX) to every four weeks. Dose reductions of 20–25% are applied when toxicity limits standard dosing. Growth factor support (G-CSF such as filgrastim or pegfilgrastim) is used prophylactically with highly myelosuppressive regimens to reduce febrile neutropenia risk. Metronomic chemotherapy — continuous low-dose oral administration of cytotoxics (cyclophosphamide, capecitabine) — exerts anti-angiogenic and immunomodulatory effects with reduced toxicity, used in elderly, frail, or heavily pre-treated patients. Granulocyte colony-stimulating factor (G-CSF, filgrastim, pegfilgrastim) is used prophylactically with highly myelosuppressive regimens to reduce febrile neutropenia risk and maintain dose intensity across cycles.

The benefit of chemotherapy varies profoundly by cancer type, stage, and intent. In curative settings — early-stage breast cancer, Hodgkin lymphoma, testicular cancer, childhood ALL — chemotherapy-based regimens produce five-year survival rates above 80–95%. Adjuvant chemotherapy for Stage III colon cancer with FOLFOX reduces the risk of recurrence by approximately 25% relative risk reduction, translating into 5–10% absolute improvement in five-year survival. For Stage I–II breast cancer with high-risk features, adjuvant chemotherapy improves ten-year overall survival by 7–10% absolute.

In the palliative setting for metastatic cancer, chemotherapy extends median survival, controls symptoms such as pain and dyspnoea from tumour bulk, and maintains quality of life. Modern combination chemotherapy plus immunotherapy — first-line pembrolizumab plus chemotherapy for advanced NSCLC, atezolizumab plus bevacizumab plus FOLFOXIRI for metastatic colorectal cancer — has extended median overall survival in major trials from 12–14 months to 20–25+ months in unselected patients. In haematological malignancies — leukaemia, lymphoma, multiple myeloma — chemotherapy forms the backbone of treatment plans that are often curative. Decisions on expected benefit are discussed individually by the oncologist, guided by tumour molecular profiling, predictive biomarkers, and established clinical trial data.

Myelosuppression — reduction in bone marrow production of white blood cells, red blood cells, and platelets — is the most common dose-limiting toxicity of most chemotherapy regimens. Neutropenia (low white blood cells) creates risk of potentially fatal febrile neutropenia — fever in a neutropenic patient requiring immediate hospitalisation and broad-spectrum intravenous antibiotics. Anaemia causes fatigue and functional limitation; thrombocytopenia causes bleeding risk. Nadir of blood counts typically occurs seven to fourteen days after each cycle.

Nausea and vomiting, once the most feared chemotherapy side effect, are now substantially controlled with 5-HT3 antagonists (ondansetron), NK1 receptor antagonists (aprepitant), and dexamethasone combinations. Highly emetogenic regimens (cisplatin) still cause significant nausea in 20–30% of patients despite prophylaxis. Peripheral neuropathy — numbness, tingling, and pain in the hands and feet — from platinum agents and taxanes is dose-dependent, often cumulative, and can be permanent after high cumulative doses. Hair loss (alopecia) is complete with anthracycline-taxane regimens and distressing for most patients; cold cap scalp cooling reduces hair loss in some regimens. Mucositis (painful mouth sores), diarrhoea (irinotecan, 5-FU), renal tubular damage (cisplatin), and cardiac dysfunction (anthracyclines — lifetime doxorubicin equivalent dose not to exceed 450–500 mg/m²) are specific major toxicities requiring careful monitoring.

Patients receiving chemotherapy are reviewed before every cycle — blood counts, symptoms, toxicity assessment, and dose modification decisions are made by the oncologist or haematologist. Dose reductions (typically 20–25%) are applied for significant toxicities. Treatment delays of one to two weeks allow bone marrow recovery. A full blood count with differential is checked on day eight to fourteen post-cycle (nadir) for highly myelosuppressive regimens to detect severe neutropenia requiring growth factor or dose reduction adjustment.

After completing planned chemotherapy, response assessment by CT, PET-CT, or tumour markers is performed four to eight weeks after the final cycle. Long-term follow-up for survivorship care includes monitoring for late effects — treatment-related secondary malignancy risk (small but real with alkylating agents), cardiac function surveillance after anthracyclines (echocardiogram at one and five years), neuropathy management, fertility assessment (for patients of reproductive age), and psychological support for anxiety and depression common in cancer survivors. Nutritional support during chemotherapy, exercise physiology and rehabilitation, and specialist palliative care input for advanced disease are integral components of comprehensive cancer care.

Chemotherapy costs vary enormously by regimen. In the United States, a six-cycle adjuvant AC-T regimen for breast cancer costs USD 25,000–80,000 for drug costs alone, with additional hospital or infusion centre charges bringing total treatment costs to USD 50,000–150,000. Novel immunotherapy-chemotherapy combinations (pembrolizumab plus carboplatin-paclitaxel) can cost USD 150,000–300,000 per year. In India, JCI-accredited oncology centres including Tata Memorial Hospital, Apollo Cancer Centres, Fortis Cancer Institute, and HCG Cancer Hospitals deliver chemotherapy with equivalent regimens at 70–90% lower drug and facility costs — a full AC-T regimen costs approximately USD 3,000–8,000, with pembrolizumab-chemotherapy combinations available at significantly reduced costs through biosimilar and generic programmes.

Thailand (Bumrungrad, BNH Hospital, Vejthani Cancer Centre) charges USD 8,000–25,000 for comparable chemotherapy regimens; Turkey (Acibadem Cancer Centre, Memorial Hospital) USD 6,000–20,000; Singapore (National Cancer Centre) USD 12,000–40,000 with high quality standards but less cost advantage. For patients seeking chemotherapy abroad, the key considerations are continuity of care (ongoing cycles and monitoring over months to years), access to the full range of supportive care including anti-emetics, growth factors, and blood products, local complication management capability, and reliable communication between home-country and treating oncologists.

Targeted therapy with small molecule inhibitors or monoclonal antibodies targets specific molecular aberrations in cancer cells, providing more selective cytotoxicity with different — and sometimes more manageable — side effect profiles than conventional chemotherapy. Examples include EGFR inhibitors (erlotinib, osimertinib) for EGFR-mutant NSCLC, HER2-targeted agents (trastuzumab, pertuzumab, trastuzumab-deruxtecan) for HER2-positive breast and gastric cancer, BRAF inhibitors (vemurafenib, dabrafenib) for BRAF-mutant melanoma, and CDK4/6 inhibitors (palbociclib, ribociclib) for hormone receptor-positive breast cancer.

Immunotherapy with immune checkpoint inhibitors (anti-PD-1: pembrolizumab, nivolumab; anti-CTLA-4: ipilimumab; anti-PD-L1: atezolizumab, durvalumab) harnesses the patient's own immune system to recognise and destroy cancer cells, producing durable responses in a subset of patients with MSI-high tumours, melanoma, NSCLC, and bladder cancer. CAR-T cell therapy — engineering the patient's own T-cells to recognise cancer antigens — has produced remarkable results in relapsed/refractory B-cell lymphomas and leukaemias. Radiotherapy, surgery, hormone therapy, and supportive care each have roles in cancer management that may complement, replace, or be used sequentially with chemotherapy depending on the cancer type and stage.